The CGT market is evolving rapidly, with billions in investments and thousands of strategic deals shaping its trajectory. Companies that understand the landscape and anticipate future deal trends will have the competitive edge needed to thrive. Whether you are a biotech executive, investor, R&D leader, or regulatory strategist, this report provides data-driven insights to inform your next move.

TWO REPORTS FOR THE PRICE OF ONE

Cell and Gene Therapy Market Deals: Investment, M&A, and Partnerships, 2021-2025 (3rd Edition) is published in two installments. The first installment, released in February 2025, covers deals up to the end of 2024. The second installment will be released in Fall 2025 and will cover deals through September 2025. Customers who purchase this third edition will receive both installments. The report covers deals including financing, funding, partnering, M&A, tech transfers, IPOs/SPACs, and other deals.

Cell and Gene Therapy Market Deals: Investment, M&A, and Partnerships, 2021-2025 (3rd Edition) is also the companion to another 2025 Kalorama Information report, Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts 2024-2030 (4th Edition), which will be released in Spring 2025. The report focuses on cell and gene therapy for disease segments including oncology, neurology, musculoskeletal, dermatology, cardiology/non-oncology blood, and more.

ABSTRACT

The cell and gene therapy (CGT)  field is at the forefront of medical innovation, fueled by cutting-edge advancements in CRISPR, next-generation sequencing (NGS), and breakthrough therapeutics. With around 2,000 companies actively engaged in the CGT industry, the sector has witnessed significant volumes of investments, strategic collaborations, and groundbreaking deals. However, shifting market dynamics—including fluctuating availability of funding of different types, evolving regulatory landscapes, and consolidation trends—have reshaped the investment outlook.

Kalorama Information’s new report, Cell and Gene Therapy Market Deals: Investment, M&A, and Partnerships, 2021-2025 (3rd Edition), delivers an unparalleled deep dive into the CGT market’s financial ecosystem, offering actionable insights into the deals that are driving the future of regenerative medicine.

Report Features

• Investment & Funding Trends – Track quarterly funding fluctuations from Q1 2021 to Q4 2024, with a focus on venture capital, private equity, and public offerings.
• M&A and Strategic Partnerships – Understand how acquisitions, licensing agreements, manufacturing deals, and co-marketing partnerships are shaping the competitive landscape.
• Regional Market Insights – Gain a global perspective on deal activity across North America, Europe, Asia-Pacific, and emerging markets.
• Top Players & Deal-Making Trends – Identify the industry’s most active investors, biotech startups, and pharmaceutical leaders driving CGT growth.
• Regulatory & Market Challenges – Explore how regulatory shifts, reimbursement strategies, and supply chain dynamics impact CGT deal-making.

In addition, the following is just some of the information in this report:

• Quarterly Funding Amounts Q1 2021- Q4 2024 by Type and Region
• Specific details of 2,000+ CGT Deals from 2021 through 2024
• Venture Capital/Private Funding Round Amounts, By Quarter
• Monthly VC/Private Funding, by Seed/ Angel, Series A/ B/ C/ D or PIPE/ direct offering
• Chronological Trends Presented in Multiple Categories (VC, M&A, Other Areas)
• Deals by Type – Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture
• Most Active Deal-Making Companies, by Type of Deal (Acquisition/Merger/ Strategic Investment, Overall Deals, Collaborations)
• Regional Breakdown of Dealmaking [North America, Europe, APAC, Rest of World] (%)

Methodology

The report’s insights are derived from a blend of primary and secondary research, including interviews with industry professionals, comprehensive literature reviews, and analysis of company and government reports.